[go: up one dir, main page]

CL2017001720A1 - Nuevos derivados de bencimidazol como agentes antihistamínicos. - Google Patents

Nuevos derivados de bencimidazol como agentes antihistamínicos.

Info

Publication number
CL2017001720A1
CL2017001720A1 CL2017001720A CL2017001720A CL2017001720A1 CL 2017001720 A1 CL2017001720 A1 CL 2017001720A1 CL 2017001720 A CL2017001720 A CL 2017001720A CL 2017001720 A CL2017001720 A CL 2017001720A CL 2017001720 A1 CL2017001720 A1 CL 2017001720A1
Authority
CL
Chile
Prior art keywords
benzimidazole derivatives
antihistamine agents
new benzimidazole
same
compounds
Prior art date
Application number
CL2017001720A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernández
Solanes Rosa Rodes
Tizne Roberto Olivera
Royo Víctor Rubio
GÓMEZ Francisco LEDO
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of CL2017001720A1 publication Critical patent/CL2017001720A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>LA INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA (I): O UNA SAL O UN SOLVATO FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS, A UN MÉTODO DE SÍNTESIS DE DICHOS COMPUESTOS, A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS MISMOS Y A SU USO EN EL TRATAMIENTO Y/O LA PREVENCIÓN DE ESTADOS MEDIADOS POR EL RECEPTOR HISTAMÍNICO H1, TALES COMO ENFERMEDADES O TRASTORNOS ALÉRGICOS.</p>
CL2017001720A 2014-12-29 2017-06-28 Nuevos derivados de bencimidazol como agentes antihistamínicos. CL2017001720A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14382576.8A EP3040334A1 (en) 2014-12-29 2014-12-29 New benzimidazole derivatives as antihistamine agents

Publications (1)

Publication Number Publication Date
CL2017001720A1 true CL2017001720A1 (es) 2018-03-16

Family

ID=52302107

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001720A CL2017001720A1 (es) 2014-12-29 2017-06-28 Nuevos derivados de bencimidazol como agentes antihistamínicos.

Country Status (17)

Country Link
US (1) US10106522B2 (es)
EP (2) EP3040334A1 (es)
JP (1) JP6585718B2 (es)
KR (1) KR20170097669A (es)
CN (1) CN107108575B (es)
AU (1) AU2015373457B2 (es)
BR (1) BR112017013998A2 (es)
CA (1) CA2970854A1 (es)
CL (1) CL2017001720A1 (es)
CO (1) CO2017005806A2 (es)
EA (1) EA033827B1 (es)
ES (1) ES2706475T3 (es)
MX (1) MX371102B (es)
PE (1) PE20171089A1 (es)
PT (1) PT3240783T (es)
WO (1) WO2016107848A1 (es)
ZA (1) ZA201704462B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents
DK3681475T3 (da) * 2017-10-16 2021-02-01 Faes Farma Sa Vandige sammensætninger omfattende bilastin og mometason
EP3915539A1 (en) 2018-01-18 2021-12-01 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
MY206632A (en) 2018-07-25 2024-12-27 Faes Farma Sa Pyridopyrimidines as histamine h4-receptor inhibitors
DE102019211434B3 (de) 2019-07-31 2020-11-05 Premium Aerotec Gmbh Spantkomponente und verfahren zur herstellung einer spantkomponente, spant und rumpfstruktur für ein luftfahrzeug
CA3243849A1 (en) 2022-02-17 2023-08-24 Faes Farma, S.A. COMPOSITION OF BILASTIN FOR ONCE-DAILY PARENTERAL ADMINISTRATION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238863A (en) * 1990-07-19 1993-03-26 Janssen Pharmaceutica Nv Substituted thiazolyl and pyridinyl derivatives
ES2048109B1 (es) * 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
JP2001011050A (ja) * 1999-04-30 2001-01-16 Sankyo Co Ltd 含窒素飽和複素環化合物
WO2002034719A1 (en) * 2000-04-21 2002-05-02 Sankyo Company, Limited Nitrogenous saturated heterocycle compounds
ES2165274B1 (es) * 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
AU2002212683A1 (en) * 2000-10-30 2002-05-15 Sankyo Company, Limited Preventive or therapeutic medicines for hepatitis and/or hepatopathy
JP2002322059A (ja) * 2001-04-25 2002-11-08 Sankyo Co Ltd 炎症性腸疾患の予防又は治療剤
CN103896915A (zh) * 2014-04-01 2014-07-02 中国药科大学 苯并咪唑类衍生物、其制备方法及其在医药上的应用
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents

Also Published As

Publication number Publication date
AU2015373457B2 (en) 2019-09-19
AU2015373457A1 (en) 2017-07-27
MX2017008495A (es) 2017-09-19
EA201791480A1 (ru) 2017-11-30
JP2018502075A (ja) 2018-01-25
JP6585718B2 (ja) 2019-10-02
PT3240783T (pt) 2019-01-28
ES2706475T3 (es) 2019-03-29
CA2970854A1 (en) 2016-07-07
EP3040334A1 (en) 2016-07-06
KR20170097669A (ko) 2017-08-28
US10106522B2 (en) 2018-10-23
CN107108575B (zh) 2019-07-26
EA033827B1 (ru) 2019-11-29
EP3240783B1 (en) 2018-11-21
CN107108575A (zh) 2017-08-29
CO2017005806A2 (es) 2017-09-20
ZA201704462B (en) 2019-09-25
US20180016251A1 (en) 2018-01-18
BR112017013998A2 (pt) 2018-03-06
MX371102B (es) 2020-01-16
PE20171089A1 (es) 2017-08-03
EP3240783A1 (en) 2017-11-08
WO2016107848A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017001720A1 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos.
MX2016009013A (es) Derivados de heterociclilo biciclicos como inhibores de cinasa-4 asociada al receptor de interleucina-1 (irak4).
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
CO6741217A2 (es) Modulares de receptor de glucagón
MX2016017147A (es) Compuestos de indazole substituidos como inhibidores de irak4.
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
SV2016005313A (es) Derivados de carboxamida
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
UY36123A (es) Derivados de carboxamida
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
UY35158A (es) ?moduladores selectivos del receptor de andrógenos novedosos?.
JOP20200030A1 (ar) مركب خماسي الحلقة
MX2019010993A (es) Derivados de tetrahidroquinolina como antagonistas del receptor p2x7.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
CL2017002605A1 (es) Derivados de indol